Effect of Bifidobacterium animalis subsp. lactis Langg JZ-08 on lipid metabolism in individuals with obesity and dyslipidemia: A randomised, double-blind, and placebo-controlled trial

IF 1.8 Q3 ENDOCRINOLOGY & METABOLISM
Xiaokang Niu , Qi Zhang , Yong Zhang , Ran Wang , Kai Yao , Yue Sang , Bing Fang , Yuyang Zhao , Liwei Liu , Langrun Wang , Rong Liu , Yixuan Li , Meiwen Sun , Hong Cui , Yinghua Liu , Jingjing He
{"title":"Effect of Bifidobacterium animalis subsp. lactis Langg JZ-08 on lipid metabolism in individuals with obesity and dyslipidemia: A randomised, double-blind, and placebo-controlled trial","authors":"Xiaokang Niu ,&nbsp;Qi Zhang ,&nbsp;Yong Zhang ,&nbsp;Ran Wang ,&nbsp;Kai Yao ,&nbsp;Yue Sang ,&nbsp;Bing Fang ,&nbsp;Yuyang Zhao ,&nbsp;Liwei Liu ,&nbsp;Langrun Wang ,&nbsp;Rong Liu ,&nbsp;Yixuan Li ,&nbsp;Meiwen Sun ,&nbsp;Hong Cui ,&nbsp;Yinghua Liu ,&nbsp;Jingjing He","doi":"10.1016/j.hnm.2025.200300","DOIUrl":null,"url":null,"abstract":"<div><div>Dyslipidemia is an established risk factor for cardiovascular disease, especially for individuals with obesity. Probiotics have been studied for their potential lipid-lowering properties, but the evidence in individuals with obesity and dyslipidemia is limited. For trial feasibility purposes, this study explored the effects of <em>Bifidobacterium animalis</em> subsp. <em>lactis</em> Langg JZ-08 (Langg JZ-08) on lipid metabolism in individuals with obesity and dyslipidemia. In a randomized, double-blind, placebo-controlled pilot trial, 40 individuals (7 males and 13 females in the placebo group, 10 males and 10 females in the probiotic group) with obesity and dyslipidemia, aged 18–65 years consumed daily probiotics (5 × 10<sup>10</sup> CFU/day Langg JZ-08) or placebo for 12 weeks. Body composition, blood lipids, markers of glycometabolism, antioxidants, and inflammation were measured before and after the intervention. Langg JZ-08 consumption significantly decreased low-density lipoprotein cholesterol (<em>P</em> = 0.01), body fat percentage (<em>P</em> = 0.01), visceral fat area (<em>P</em> = 0.04), serum insulin (<em>P</em> = 0.01), glycosylated hemoglobin (<em>P</em> = 0.02), tumor necrosis factor-α (<em>P</em> &lt; 0.05), and increased glutathione peroxidase (GPX) (<em>P</em> &lt; 0.001) and total antioxidant capacity (T-AOC) (<em>P</em> &lt; 0.01) compared to the baseline. The decrease in total cholesterol was significantly greater in the probiotic group than in the placebo group after 12 weeks of intervention (<em>P</em> = 0.04). After the intervention, the serum superoxide dismutase, GPX and T-AOC levels were significantly higher in the Langg JZ-08 group than that of the placebo group (<em>P</em> &lt; 0.05). There were no significant inter- and intra-group differences in triglycerides, high-density lipoprotein cholesterol, body mass index, waist, hip, and fasting blood glucose after the intervention. 12-week Langg JZ-08 intervention improved lipid metabolism, oxidative stress, and inflammation in individuals with obesity and dyslipidemia. This pilot trial supports the feasibility of a larger scale randomized controlled trial to determine the efficacy of Langg JZ-08 on obesity with dyslipidemia.</div></div>","PeriodicalId":36125,"journal":{"name":"Human Nutrition and Metabolism","volume":"40 ","pages":"Article 200300"},"PeriodicalIF":1.8000,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Nutrition and Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666149725000039","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Dyslipidemia is an established risk factor for cardiovascular disease, especially for individuals with obesity. Probiotics have been studied for their potential lipid-lowering properties, but the evidence in individuals with obesity and dyslipidemia is limited. For trial feasibility purposes, this study explored the effects of Bifidobacterium animalis subsp. lactis Langg JZ-08 (Langg JZ-08) on lipid metabolism in individuals with obesity and dyslipidemia. In a randomized, double-blind, placebo-controlled pilot trial, 40 individuals (7 males and 13 females in the placebo group, 10 males and 10 females in the probiotic group) with obesity and dyslipidemia, aged 18–65 years consumed daily probiotics (5 × 1010 CFU/day Langg JZ-08) or placebo for 12 weeks. Body composition, blood lipids, markers of glycometabolism, antioxidants, and inflammation were measured before and after the intervention. Langg JZ-08 consumption significantly decreased low-density lipoprotein cholesterol (P = 0.01), body fat percentage (P = 0.01), visceral fat area (P = 0.04), serum insulin (P = 0.01), glycosylated hemoglobin (P = 0.02), tumor necrosis factor-α (P < 0.05), and increased glutathione peroxidase (GPX) (P < 0.001) and total antioxidant capacity (T-AOC) (P < 0.01) compared to the baseline. The decrease in total cholesterol was significantly greater in the probiotic group than in the placebo group after 12 weeks of intervention (P = 0.04). After the intervention, the serum superoxide dismutase, GPX and T-AOC levels were significantly higher in the Langg JZ-08 group than that of the placebo group (P < 0.05). There were no significant inter- and intra-group differences in triglycerides, high-density lipoprotein cholesterol, body mass index, waist, hip, and fasting blood glucose after the intervention. 12-week Langg JZ-08 intervention improved lipid metabolism, oxidative stress, and inflammation in individuals with obesity and dyslipidemia. This pilot trial supports the feasibility of a larger scale randomized controlled trial to determine the efficacy of Langg JZ-08 on obesity with dyslipidemia.
动物双歧杆菌的作用。lactis lang JZ-08对肥胖和血脂异常患者脂质代谢的影响:一项随机、双盲、安慰剂对照试验
血脂异常是心血管疾病的一个确定的危险因素,特别是对于肥胖个体。益生菌因其潜在的降脂特性而被研究,但在肥胖和血脂异常人群中的证据有限。为了试验的可行性,本研究探讨了动物双歧杆菌亚种的作用。lactis langjz -08 (langjz -08)对肥胖和血脂异常个体脂质代谢的影响。在一项随机、双盲、安慰剂对照的先导试验中,40名年龄在18-65岁的肥胖和血脂异常患者(安慰剂组7名男性和13名女性,益生菌组10名男性和10名女性)每天服用益生菌(5 × 1010 CFU/天)或安慰剂12周。在干预前后测量身体成分、血脂、糖代谢标志物、抗氧化剂和炎症。Langg JZ-08显著降低了低密度脂蛋白胆固醇(P = 0.01)、体脂率(P = 0.01)、内脏脂肪面积(P = 0.04)、血清胰岛素(P = 0.01)、糖化血红蛋白(P = 0.02)、肿瘤坏死因子-α (P <;0.05),谷胱甘肽过氧化物酶(GPX)升高(P <;0.001)和总抗氧化能力(T-AOC) (P <;0.01)。干预12周后,益生菌组总胆固醇的下降明显大于安慰剂组(P = 0.04)。干预后,langang JZ-08组血清超氧化物歧化酶、GPX、T-AOC水平均显著高于安慰剂组(P <;0.05)。干预后,各组间和组内甘油三酯、高密度脂蛋白胆固醇、体重指数、腰围、臀部和空腹血糖均无显著差异。12周的Langg JZ-08干预可改善肥胖和血脂异常患者的脂质代谢、氧化应激和炎症。本试验支持开展更大规模的随机对照试验,以确定朗格JZ-08对肥胖合并血脂异常的疗效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Human Nutrition and Metabolism
Human Nutrition and Metabolism Agricultural and Biological Sciences-Food Science
CiteScore
1.50
自引率
0.00%
发文量
30
审稿时长
188 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信